Biotechnology company Pandorum Technologies has raised $18 million in a Series B funding round to advance and market tissue regenerative therapies. Pandorum specialises in programmable regenerative ...

Biotechnology firm Pandorum Technologies has raised $18 million (Rs 163 crore) in a Series B round to advance the clinical development of its therapies that target diseases on the surface of the eye.

Pandorum Technologies has raised $18 million in a Series B funding round to advance clinical development and expand market access for its regenerative therapies. The India and US-based biotechnology ...

Pandorum Technologies, a biotechnology company focused on programmable regenerative medicine, has raised $18 million in a Series B funding round to advance clinical development and expand global ...

The funding round led by Protons Corporate, with participation from Galentic Pharma, Noblevast Advisory and Avinya Fund, Burman Family, among others The fresh capital will be deployed to advance the ...

Tom Bowen is a senior editor who loves adventure games and RPGs. He's been playing video games for several decades now and writing about them professionally since 2020. Although he dabbles in news and ...

BENGALURU, India & SAN CARLOS, Calif.--(BUSINESS WIRE)--Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, ...

Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, has announced the closing of a US$ 18 million in Series B ...

Funding accelerates clinical development and market access across the U.S., Asia, and the Middle East Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with ...

Tom Bowen is a senior editor who loves adventure games and RPGs. He's been playing video games for several decades now and writing about them professionally since 2020. Although he dabbles in news and ...

QuantX will deploy Series B proceeds toward IND-enabling advancement of oral STAT6 and IL-17 inhibitors in immunology/inflammation and continued discovery expansion on its computational platform.